Scientific Background and Reference Sources
For Policy Titled: Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
ACS. (2024a). Key Statistics for Prostate Cancer. Retrieved 5/10/2024 from https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
ACS. (2024b). Survival Rates for Prostate Cancer. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/survival-rates.html
Alford, A. V., Brito, J. M., Yadav, K. K., Yadav, S. S., Tewari, A. K., & Renzulli, J. (2017). The Use of Biomarkers in Prostate Cancer Screening and Treatment. Rev Urol, 19(4), 221-234. https://pubmed.ncbi.nlm.nih.gov/29472826/
ArteraAI. (2024). New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence. https://www.businesswire.com/news/home/20240506052855/en/New-Data-Validating-the-First-AI-Based-Biomarker-to-Stratify-Risk-of-Metastasis-in-Radical-Prostatectomy-Patients-with-Biochemical-Recurrence
Bell, K. J., Del Mar, C., Wright, G., Dickinson, J., & Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer, 137(7), 1749-1757. https://doi.org/10.1002/ijc.29538
Benedettini, E., Nguyen, P., & Loda, M. (2008). The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol (Oxf), 14(5), 195-201. https://doi.org/10.1016/j.mpdhp.2008.03.001
Blume-Jensen, P., Berman, D. M., Rimm, D. L., Shipitsin, M., Putzi, M., Nifong, T. P., . . . Saad, F. (2015). Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res, 21(11), 2591-2600. https://doi.org/10.1158/1078-0432.Ccr-14- 2603
Carneiro, A., Priante Kayano, P., Gomes Barbosa, Á. R., Langer Wroclawski, M., Ko Chen, C., Cavlini, G. C., . . . Bianco, B. (2018). Are localized prostate cancer biomarkers useful in the clinical practice? Tumor Biology, 40(9), 1010428318799255. https://doi.org/10.1177/1010428318799255
Chen, X., Bernemann, C., Tolkach, Y., Heller, M., Nientiedt, C., Falkenstein, M., . . . Duensing, S. (2018). Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urol Oncol, 36(4), 161.e119-161.e130. https://doi.org/10.1016/j.urolonc.2017.11.001
Couñago, F., López-Campos, F., Díaz-Gavela, A. A., Almagro, E., Fenández-Pascual, E., Henríquez, I., . . . Del Cerro, E. (2020). Clinical Applications of Molecular Biomarkers in Prostate Cancer. Cancers (Basel), 12(6). https://doi.org/10.3390/cancers12061550
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., . . . McLeod, D. G. (2015). A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. Eur Urol, 68(1), 123-131. https://doi.org/10.1016/j.eururo.2014.11.030
Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., . . . Scardino, P. (2015). Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer, 113(3), 382-389. https://doi.org/10.1038/bjc.2015.223
Dalela, D., Löppenberg, B., Sood, A., Sammon, J., & Abdollah, F. (2016). Contemporary Role of the Decipher® Test in Prostate Cancer Management: Current Practice and Future Perspectives. Rev Urol, 18(1), 1-9.
Davis, J. W. (2014). Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU International, 114(3), 320-322. https://doi.org/10.1111/bju.12695
Duffy, M. J. (2020). Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med, 58(3), 326-339. https://doi.org/10.1515/cclm-2019-0693
Eggener, S. E., Rumble, R. B., Armstrong, A. J., Morgan, T. M., Crispino, T., Cornford, P., . . . Beltran, H. (2020). Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol, Jco1902768. https://doi.org/10.1200/jco.19.02768
Epic Sciences. (2023). AR-V7 by Epic Sciences. https://www.epicsciences.com/ar-v7-test/
Esteva, A., Feng, J., van der Wal, D., Huang, S.-C., Simko, J. P., DeVries, S., Chen, E., Schaeffer, E. M., Morgan, T. M., Sun, Y., Ghorbani, A., Naik, N., Nathawani, D., Socher, R., Michalski, J. M., Roach, M., Pisansky, T. M., Monson, J. M., Naz, F., . . . Consortium, N. R. G. P. C. A. (2022). Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. npj Digital Medicine, 5(1), 71. https://doi.org/10.1038/s41746-022-00613-w
Exact Sciences. (2021). A Tailored Report for Clinically Low Risk Prostate Cancer Patients https://d2ft3j3kbsqj8w.cloudfront.net/-/media/Project/PrecisionOncology/PrecisionOncology/OIQ-Reports/Prostate/GPS-Interactive-Report-Tool/GPSRE_GPS_Annotated_Report-2- Pager_M_US_GPS_00374.pdf?rev=50c0c67b355241178c9deba9609ded65
ExoSome. (2024a). ExoDx™ Prostate Test. Retrieved 2/8/21 from http://www.exosomedx.com/physicians/exodx-prostate-test
ExoSome. (2024b). Prostate Cancer. http://www.exosomedx.com/prostate-cancer-0
Gittelman, M. C., Hertzman, B., Bailen, J., Williams, T., Koziol, I., Henderson, R. J., . . . Ward, J. F. (2013). PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol, 190(1), 64-69. https://doi.org/10.1016/j.juro.2013.02.018
Graf, R. P., Hullings, M., Barnett, E. S., Carbone, E., Dittamore, R., & Scher, H. I. (2020). Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. Eur Urol, 77(2), 170-177. https://doi.org/10.1016/j.eururo.2019.08.020
Hannah Clarke. (2024). ArteraAI Prostate Test included in NCCN guidelines. Urology Times. https://www.urologytimes.com/view/arteraai-prostate-cancer-test-included-in-nccn-guidelines
Hoffman, R. (2023). Screening for prostate cancer. https://www.uptodate.com/contents/screening-for-prostate-cancer
Hologic. (2024). Progensa Brochure. https://stage.hologic.com/sites/default/files/package-insert/Progensa%20PCA3%20Physician%20Brochure-USA.pdf
Hu, J. C., Tosoian, J. J., Qi, J., Kaye, D., Johnson, A., Linsell, S., . . . Morgan, T. M. (2018). Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. (2), 1-15. https://doi.org/10.1200/po.18.00163
Jia, W., Wu, B., Shao, Y., Cao, X., & Wang, D. (2020). Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis. International Journal of Urology, n/a(n/a). https://doi.org/10.1111/iju.14464
Klein, E. A., Partin, A., Lotan, Y., Baniel, J., Dineen, M., Hafron, J., Manickam, K., Pliskin, M., Wagner, M., Kestranek, A., & Stovsky, M. (2022). Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. Urol Oncol, 40(9), 408 e409-408 e418. https://doi.org/10.1016/j.urolonc.2022.06.002
Lin, D. W., Crawford, E. D., Keane, T., Evans, B., Reid, J., Rajamani, S., . . . Cuzick, J. (2018). Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations, 36(6), 310.e317-310.e313. https://doi.org/10.1016/j.urolonc.2018.03.011
Lotan, T. L., Gurel, B., Sutcliffe, S., Esopi, D., Liu, W., Xu, J., . . . De Marzo, A. M. (2011). PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res, 17(20), 6563-6573. https://doi.org/10.1158/1078-0432.Ccr-11-1244
Marascio, J., Spratt, D. E., Zhang, J., Trabulsi, E. J., Le, T., Sedzorme, W. S., . . . Den, R. B. (2020). Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer and Prostatic Diseases, 23(2), 295-302. https://doi.org/10.1038/s41391-019-0185-7
Matuszczak, M., Schalken, J. A., & Salagierski, M. (2021). Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis. Cancers (Basel), 13(13). https://doi.org/10.3390/cancers13133373
McKiernan, J., Donovan, M. J., Margolis, E., Partin, A., Carter, B., Brown, G., . . . Carroll, P. (2018). A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur Urol, 74(6), 731-738. https://doi,org/10.1016/j.eururo.2018.08.019
McKiernan, J., Donovan, M. J., O’Neill, V., Bentink, S., Noerholm, M., Belzer, S., . . . Carroll, P. (2016). A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial BiopsyUrine Exosome Signature to Predict High-Grade Prostate CancerUrine Exosome Signature to Predict High-Grade Prostate Cancer. JAMA Oncology, 2(7), 882-889. https://doi.org/10.1001/jamaoncol.2016.0097
McKiernan, J., Noerholm, M., Tadigotla, V., Kumar, S., Torkler, P., Sant, G., Alter, J., Donovan, M. J., & Skog, J. (2020). A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy. BMC Urol, 20(1), 138. https://doi.org/10.1186/s12894-020-00712-4
MDxHealth. (2023a). ConfirmMDx for Prostate Cancer. https://mdxhealth.com/confirm-mdx-for-physicians/
MDxHealth. (2023b). SelectMDx for Prostate Cancer. https://mdxhealth.com/select-mdx-for-physicians/
Mi, C., Bai, L., Yang, Y., Duan, J., & Gao, L. (2021). 4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 10%: A meta-analysis. Urol Oncol, 39(6), 366 e361-366 e310. https:doi.org/10.1016/j.urolone.2020.11.001
Mottet, N., Cornford, P., van den Bergh, R. C. N., Briers, E., Eberli, D., De Meerleer, G., De Santis, M., Gillessen, S., Grummet, J., Henry, A. M., van der Kwast, T. H., van Leenders, G. J. L. H., Mason, M. D., O'Hanlon, S., van Oort, I. M., Oprea-Lager, D. E., Ploussard, G., Rouvière, O., Schoots, I. G., . . . Willemse, P.-P. (2023). Guidelines on Prostate Cancer. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-06-13-141145.pdf
Murphy, A. B., Carbunaru, S., Nettey, O. S., Gornbein, C., Macias, V., Sharifi, R., . . . Gann, P. (2020). A 17- Gene Panel Genomic Prostate Score has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology. https://doi.org/10.1016/j.urology.2020.01.052
NCCN. (2024a). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 4.2024—May 17, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
NCCN. (2024b). Prostate Cancer Early Detection Version 2.2024—March 6, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf
Nguyen, P. L., Huang, H. R., Spratt, D. E., Davicioni, E., Sandler, H. M., Shipley, W. U., Efstathiou, J. A., Simko, J. P., Pollack, A., Dicker, A. P., Roach, M., Rosenthal, S. A., Zeitzer, K. L., Mendez, L. C., Hartford, A. C., Hall, W. A., Desai, A. B., Rabinovitch, R. A., Peters, C. A., . . . Feng, F. Y. (2023). Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. Int J Radiat Oncol Biol Phys, 116(3), 521-529. https://doi.org/10.1016/j.ijrobp.2022.12.035
OPKO. (2021). OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test. https://www.opko.com/news-media/press-releases/detail/454/opko-health-receives-u-s-fda-approval-for-the-4kscore
Parekh, D. J., Punnen, S., Sjoberg, D. D., Asroff, S. W., Bailen, J. L., Cochran, J. S., Concepcion, R., David, R. D., Deck, K. B., Dumbadze, I., Gambla, M., Grable, M. S., Henderson, R. J., Karsh, L., Krisch, E. B., Langford, T. D., Lin, D. W., McGee, S. M., Munoz, J. J., . . . Zappala, S. M. (2015). A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol, 68(3), 464-470. https://doi.org/10.1016/j.eururo.2014.10.021
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tomball, B., & . Gillessen, S. (2020). Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 31(9), 1119-1134. doi:10.1016/j.annonc.2020.06.011
Punnen, S., Freedland, S. J., Polascik, T. J., Loeb, S., Risk, M. C., Savage, S., Mathur, S. C., Uchio, E., Dong, Y., & Silberstein, J. L. (2018). A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. J Urol, 199(6), 1459-1463. https://doi.org/10.1016/j.juro.2017.11.113
Rodríguez, S. V. M., & García-Perdomo, H. A. (2020). Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis. Can Urol Assoc J, 14(5), E214-e219. https://doi.org/10.5489/cuaj.6008
Ross, A. E., D'Amico, A. V., & Freedland, S. J. (2022). Molecular prognostic tests for prostate cancer. Wolters Kluwer. Retrieved 10/10/2023 from https://www.uptodate.com/contents/molecular-prognostic-tests-for-prostate-cancer
Sathianathen Niranjan, J., Kuntz Karen, M., Alarid-Escudero, F., Lawrentschuk Nathan, L., Bolton Damien, M., Murphy Declan, G., . . . Konety Badrinath, R. (2018). Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. Journal of Urology, 200(6), 1215-1220. doi:10.1016/j.juro.2018.06.016
Scher, H. I., Lu, D., Schreiber, N. A., Louw, J., Graf, R. P., Vargas, H. A., . . . Dittamore, R. (2016). Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate CancerAR-V7 Expression in Circulating Tumor Cells and Castration-Resistant Prostate Cancer OutcomesAR-V7 Expression in Circulating Tumor Cells and Castration-Resistant Prostate Cancer Outcomes. JAMA Oncology, 2(11), 1441-1449. doi:10.1001/jamaoncol.2016.1828
Scovell, J. M., Hettel, D., Abouassaly, R., Almassi, N., Berglund, R., Breaux, T., Weight, C., Isac, W., Zampini, A., Stark, E., Rochelle, R., Kestranek, A., Stovsky, M., & Klein, E. (2022). IsoPSA® Reduces Provider Recommendations for Biopsy and Magnetic Resonance Imaging in Men with Total Prostate Specific Antigen ≥4 ng/ml: A Real-World Observational Clinical Utility Study. https://doi.org/10.1097/UPJ.0000000000000291
Shore, N. (2018). SelectMDx Impacts Prostate Biopsy Decision-making in Routine Clinical Practice.
Song, C. J., Chen, H., Chen, L. Z., Ru, G. M., Guo, J. J., & Ding, Q. N. (2018). The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies. J Cell Biochem, 119(3), 2763- 2786. doi:10.1002/jcb.26445
Spratt, D. E., Liu, V. Y. T., Michalski, J., Davicioni, E., Berlin, A., Simko, J. P., Efstathiou, J. A., Tran, P. T., Sandler, H. M., Hall, W. A., Thompson, D. J. S., Parliament, M. B., Dayes, I. S., Correa, R. J. M., Robertson, J. M., Gore, E. M., Doncals, D. E., Vigneault, E., Souhami, L., . . . Feng, F. Y. (2023). Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. International Journal of Radiation Oncology, Biology, Physics, 117(2), 370-377. https://doi.org/10.1016/j.ijrobp.2023.04.010
Steiling, K., & Christenson, S. (2023, 10/10/2023). Tools for genetics and genomics: Gene expression profiling. Retrieved from https://www.uptodate.com/contents/tools-for-genetics-and-genomics-gene-expression-profiling
Stovsky, M., Klein, E. A., Chait, A., Manickam, K., Stephenson, A. J., Wagner, M., Dineen, M., Lotan, Y., Partin, A., Baniel, J., Kestranek, A., Gawande, P., & Boris, Z. (2019). Clinical Validation of IsoPSA, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. J Urol, 201(6), 1115-1120. https://doi.org/10.1097/JU.0000000000000185
Taplin, M.-E., & Smith, J. A. (2024, 3/22/2024). Clinical presentation and diagnosis of prostate cancer. https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer
Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., Dunn, R. L., Meyer, S., Hodge, P., Groskopf, J., Wei, J. T., & Chinnaiyan, A. M. (2016). Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol, 70(1), 45-53. https://doi.org/10.1016/j.eururo.2015.04.039
Tosoian, J. J., Trock, B. J., Morgan, T. M., Salami, S. S., Tomlins, S. A., Spratt, D. E., Siddiqui, J., Kunju, L. P., Botbyl, R., Chopra, Z., Pandian, B., Eyrich, N. W., Longton, G., Zheng, Y., Palapattu, G. S., Wei, J. T., Niknafs, Y. S., & Chinnaiyan, A. M. (2021). Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. J Urol, 205(3), 732-739. https://doi.org/10.1097/JU.0000000000001430
Tutrone, R., Donovan, M. J., Torkler, P., Tadigotla, V., McLain, T., Noerholm, M., Skog, J., & McKiernan, J. (2020). Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL. Prostate Cancer Prostatic Dis. doi:10.1038/s41391-020-0237-z
Tward, J. D., Schlomm, T., Bardot, S., Freedland, S. J., Lenz, L., Cohen, T., . . . Bishoff, J. (2020). Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. Journal of Clinical Oncology, 38(6_suppl), 346-346. doi:10.1200/JCO.2020.38.6_suppl.346
Van den Broeck, T., Moris, L., Gevaert, T., Tosco, L., Smeets, E., Fishbane, N., . . . Joniau, S. (2019). Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. Eur Urol Oncol, 2(5), 589-596. doi:10.1016/j.euo.2018.12.007
Van Neste, L., Hendriks, R. J., Dijkstra, S., Trooskens, G., Cornel, E. B., Jannink, S. A., . . . Schalken, J. A. (2016). Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol, 70(5), 740-748. doi:10.1016/j.eururo.2016.04.012
Van Neste, L., Partin, A. W., Stewart, G. D., Epstein, J. I., Harrison, D. J., & Van Criekinge, W. (2016). Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate, 76(12), 1078-1087. doi:10.1002/pros.23191
White, J., Shenoy, B. V., Tutrone, R. F., Karsh, L. I., Saltzstein, D. R., Harmon, W. J., Broyles, D. L., Roddy, T. E., Lofaro, L. R., Paoli, C. J., Denham, D., & Reynolds, M. A. (2018). Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis, 21(1), 78-84. https://doi.org/10.1038/s41391-017-0008-7
Wojno, K. J., Costa, F. J., Cornell, R. J., Small, J. D., Pasin, E., Van Criekinge, W., . . . Van Neste, L. (2014). Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. Am Health Drug Benefits, 7(3), 129-134. https://pubmed.ncbi.nlm.nih.gov/24991397/
Wysock, J. S., Becher, E., Persily, J., Loeb, S., & Lepor, H. (2020). Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. Urology, 141, 119-124. doi:10.1016/j.urology.2020.02.032
Zappala, S. M., Scardino, P. T., Okrongly, D., Linder, V., & Dong, Y. (2017). Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. Rev Urol, 19(3), 149-155. doi:10.3909/riu0776
Medical Director review 4/2020
Medical Director review 7/2020
Specialty Matched Consultant Panel 8/2020
Medical Director review 1/2021
For Policy Titled: Gene Expression Profiling and Protein Biomarkers for Prostate Cancer
Medical Director review 4/2021
Specialty Matched Consultant Panel 8/2021
Medical Director review 4/2022
Medical Director review 1/2023
Medical Director review 1/2024
Medical Director review 7/2024